Trulieve Cannabis Corp. (TRLV) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Trulieve Cannabis Corp. (TRLV) stock forecast summary
On Oct. 16, 2026, TRLV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
Trulieve Cannabis Corp. is a small-cap company with a market capitalization of $1.93B. It ranks number 2 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For TRLV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 56.0%, measured on 55 forecast dates between 2026-05-04 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 2.0%, measured on 98 forecast dates between 2026-05-04 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TRLV included.
Follow TRLV freeTRLV price chart and AI forecast
How TRLV ranks among 5171 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trulieve Cannabis Corp. (TRLV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | TRLV | Rank |
|---|---|---|
| Market Cap | $1.93B | 2/28 |
| P/B Ratio | 2.51x | 4/13 |
| EPS | $-2.44 | – |
| Book Value/Share | $3.99 | – |
| Revenue/Share | $5.92 | – |
| FCF/Share | $1.01 | – |
Profitability & Margins
| Metric | TRLV | Rank |
|---|---|---|
| ROE | -61.7% | 15/16 |
| ROA | -22.8% | 16/24 |
| ROIC | -14.0% | 13/20 |
| Gross Margin | 59.5% | 7/23 |
| Operating Margin | -24.3% | 16/24 |
| Net Margin | -41.5% | 16/22 |
| EBT Margin | -28.6% | 18/25 |
| Tax Rate | -44.4% | – |
Financial Health
| Metric | TRLV | Rank |
|---|---|---|
| Current Ratio | 5.94x | 4/28 |
| Quick Ratio | 3.98x | 3/26 |
| D/E Ratio | 1.71x | 5/17 |
| Financial Leverage | 2.71x | 5/17 |
| Interest Coverage | -20.5x | 17/22 |
| Working Capital | $470M | 3/28 |
Cash Flow
| Metric | TRLV | Rank |
|---|---|---|
| Operating Cash Flow | $245M | 1/29 |
| Free Cash Flow | $195M | 1/12 |
| Capital Spending | -$50M | 12/12 |
| OCF Growth YoY | 23.8% | 4/11 |
| FCF Growth YoY | 116.3% | 1/6 |
| FCF/Sales | 17.1% | 2/12 |
| CapEx/Sales | 4.4% | 3/12 |
Operational Efficiency
| Metric | TRLV | Rank |
|---|---|---|
| Asset Turnover | 0.55x | 12/17 |
| Receivables Turnover | 289.2x | 1/16 |
| Inventory Turnover | 2.5x | 13/21 |
| Fixed Assets Turnover | 1.9x | 12/17 |
| Days Sales Outstanding | 1 days | 16/16 |
| Days Inventory | 148 days | 8/20 |
| Payables Period | 49 days | 11/18 |
| Cash Conversion Cycle | 100 days | 8/12 |
Income Statement
| Metric | TRLV | Rank |
|---|---|---|
| Total Revenue | $1.14B | 2/18 |
| Operating Income | -$277M | 25/27 |
| Net Income | -$473M | 24/24 |
| SG&A Expense | $432M | 1/16 |
| Cost of Goods Sold | $462M | 2/24 |
Dividend & Shareholder Information
| Metric | TRLV | Rank |
|---|---|---|
| Shares Outstanding | 192M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $565M | 27.2% of assets |
| Cash & Short-term Investments | $325M | 15.7% of assets |
| Accounts Receivable | $4M | 0.2% of assets |
| Inventory | $187M | 9.0% of assets |
| Total Liabilities | $1.31B | 63.1% of assets |
| Short-term Debt | $34M | 1.6% of assets |
TRLV quarterly financials and insider trading
Trulieve Cannabis Corp. (TRLV) industry peers
Companies classified under the same SEC industry code as Trulieve Cannabis Corp. (Medicinal Chemicals & Botanical Products): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| TRLV Trulieve Cannabis Corp. | ▶ | $1.93B |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▶ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▶ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▼ | $157M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $83M |
| FTLF Fitlife Brands, Inc. | ▶ | $81M |
| BTMD Biote Corp. | ▲ | $32M |
| MRMD Marimed Inc. | ▲ | $23M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| CHUC Charlie's Holdings, Inc. | ▶ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $10M |
| BON Bon Natural Life Ltd | ▼ | $7M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $310K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▲ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where TRLV sits on the market map
Trulieve Cannabis Corp. (TRLV) stock news
Loading...
Trulieve Cannabis Corp. (TRLV) stock forecast FAQ
What is the Trulieve Cannabis Corp. (TRLV) stock forecast?
On Oct. 16, 2026, TRLV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Trulieve Cannabis Corp. stock predictions?
For TRLV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 56.0%, measured on 55 forecast dates between 2026-05-04 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 2.0%, measured on 98 forecast dates between 2026-05-04 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Trulieve Cannabis Corp. forecasts updated?
Trulieve Cannabis Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Trulieve Cannabis Corp.'s industry peers?
32 issuers in our coverage, TRLV included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC), Glass House Brands Inc. (GLAS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.